Understanding the drivers of beneficial patient response with ACE ImmunoID™

Checkpoint inhibitors and modulators have shown great promise in the treatment of cancer, but response rates have been limited. We need a deeper understanding of cancer biology in order to better comprehend the drivers of beneficial and sustained response. ACE ImmunoID™ leverages proprietary technology from Personalis to augment DNA and RNA sequencing; helping scientists and researchers gain a more complete genomic picture to ultimately develop safer and more effective cancer immunotherapies.